2702 related articles for article (PubMed ID: 26619946)
21. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
22. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
23. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
[TBL] [Abstract][Full Text] [Related]
24. Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
Tang T; Eldabaje R; Yang L
Anticancer Res; 2016 Jul; 36(7):3229-41. PubMed ID: 27354579
[TBL] [Abstract][Full Text] [Related]
25. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
Johnson DB; Sosman JA
JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
[TBL] [Abstract][Full Text] [Related]
27. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
28. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
[TBL] [Abstract][Full Text] [Related]
29. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).
Ascierto PA; Blank C; Dummer R; Ernstoff MS; Ferrone S; Fox BA; Gajewski TF; Garbe C; Hwu P; Kalinski P; Krogsgaard M; Lo RS; Luke JJ; Neyns B; Postow MA; Quezada SA; Teng MWL; Trinchieri G; Testori A; Caracò C; Osman I; Puzanov I; Thurin M
J Transl Med; 2021 Jun; 19(1):278. PubMed ID: 34193182
[TBL] [Abstract][Full Text] [Related]
30. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".
Ascierto PA; Grimaldi AM; Acquavella N; Borgognoni L; Calabrò L; Cascinelli N; Cesano A; Del Vecchio M; Eggermont AM; Faries M; Ferrone S; Fox BA; Gajewski TF; Galon J; Gnjatic S; Gogas H; Kashani-Sabet M; Kaufman HL; Larkin J; Lo RS; Mantovani A; Margolin K; Melief C; McArthur G; Palmieri G; Puzanov I; Ribas A; Seliger B; Sosman J; Suenaert P; Tarhini AA; Trinchieri G; Vidal-Vanaclocha F; Wang E; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2013 Jun; 11():137. PubMed ID: 23731854
[TBL] [Abstract][Full Text] [Related]
31. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.
Shah DJ; Dronca RS
Mayo Clin Proc; 2014 Apr; 89(4):504-19. PubMed ID: 24684873
[TBL] [Abstract][Full Text] [Related]
32. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Zhu Z; Liu W; Gotlieb V
Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
[TBL] [Abstract][Full Text] [Related]
33. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
34. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in
White MG; Szczepaniak Sloane R; Witt RG; Reuben A; Gaudreau PO; Andrews MC; Feng N; Johnson S; Class CA; Bristow C; Wani K; Hudgens C; Nezi L; Manzo T; De Macedo MP; Hu J; Davis R; Jiang H; Prieto P; Burton E; Hwu P; Tawbi H; Gershenwald J; Lazar AJ; Tetzlaff MT; Overwijk W; Woodman SE; Cooper ZA; Marszalek JR; Davies MA; Heffernan TP; Wargo JA
Oncoimmunology; 2021; 10(1):1992880. PubMed ID: 34777916
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
36. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
Gargett T; Fraser CK; Dotti G; Yvon ES; Brown MP
J Immunother; 2015 Jan; 38(1):12-23. PubMed ID: 25415284
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral T; Meraz-Torres F; Garbe C
Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
[TBL] [Abstract][Full Text] [Related]
38. Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives.
Malissen N; Grob JJ
Drugs; 2018 Aug; 78(12):1197-1209. PubMed ID: 30097888
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of Drug Resistance in Melanoma.
Winder M; Virós A
Handb Exp Pharmacol; 2018; 249():91-108. PubMed ID: 28275910
[TBL] [Abstract][Full Text] [Related]
40. Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.
Wood K; Luke JJ
Curr Oncol Rep; 2016 Nov; 18(11):67. PubMed ID: 27613168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
